Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Braeburn Launches Brave Action

Braeburn Pharmaceuticals
Posted on: 12 Apr 18
Braeburn Launches Brave Action New Resource For Dedicated Healthcare Professionals Treating Opioid Use Disorder

PR Newswire

PRINCETON, N.J., April 12, 2018

PRINCETON, N.J., April 12, 2018 /PRNewswire/ -- Braeburn, as part of its overall efforts to improve the lives of patients with Opioid Use Disorder (OUD), announced today the launch of Brave Action, a new disease-focused resource to support the many healthcare providers on the front lines of the U.S. opioid addiction epidemic. Brave Action aims to increase the understanding of the multi-faceted nature of OUD and provide timely access to emerging information and resources to help healthcare providers (HCPs) stay up-to-date. This initiative employs numerous elements including the launch of, a dedicated website that will provide HCPs the latest studies, reports, recommendations and other information in easy-to-digest formats.

"By providing a go-to resource with the latest information about OUD, Brave Action is intended to spark a collaborative partnership among key stakeholders to better understand and tackle the leading healthcare crisis of our time," said Mike Derkacz, President and CEO of Braeburn. "It's critical that we all work together to advance the care of these patients and continue to dispel myths and remove stigmas associated with this chronic brain disease."

Further information about this initiative will be made available at the Brave Action booth during the American Society of Addition Medicine (ASAM) Annual Conference this week in San Diego. Information may also be accessed anytime at  

About Braeburn Pharmaceuticals

Braeburn is a pharmaceutical company dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid addiction. The company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients, healthcare professionals, payers and society. For more information about Braeburn, please visit

For additional information, please contact:

Media Relations:
Colleen Saltmer:

Investor Relations:
Chris Taylor:


View original content with multimedia:

SOURCE Braeburn Pharmaceuticals

PR Newswire

Last updated on: 12/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.